Formulary
Ciprofibrate: Indications, Dosing, Side Effects and Interactions
Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.
MedNext Academy | 3 min read
Ciprofibrate: Indications, Dosing, Side Effects and Interactions
Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.
Drug action
Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.
Indications and dose
**Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contraindicated or not tolerated,Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia**
- **Adult** (By Mouth): 100 mg daily.
Cautions
Correct hypothyroidism before initiating treatment; risk factors for myopathy
Contraindications
Gall bladder disease; hypoalbuminaemia; nephrotic syndrome; photosensitivity to fibrates
Side effects
Common or very common Alopecia; diarrhoea; dizziness; drowsiness; fatigue; gastrointestinal discomfort; headache; myalgia; nausea; skin reactions; vertigo; vomiting Frequency not known Cholelithiasis; erectile dysfunction; hepatic disorders; leucopenia; myopathy; photosensitivity reaction; pneumonitis; pulmonary fibrosis; rhabdomyolysis (increased risk in renal impairment); thrombocytopenia
Interactions
**Severe interactions:**
- Ciprofibrate has been shown to potentiate the effect of warfarin, indicating that concomitant oral anticoagulant therapy should be given at reduced dosage and adjusted according to INR (see section...
**Other interactions (1):**
- Contra-indicated combination Other fibrates: As with other fibrates, the risk of rhabdomyolysis and myoglobinuria may be increased if ciprofibrate is used in combination with other fibrates (see...
Pregnancy
Manufacturers advise avoid-toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises use with caution in mild-to-moderate impairment; avoid in severe impairment
Renal impairment
Avoid in severe impairment. M Myotoxicity Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly. M Dose adjustments Reduce dose to 100 mg on alternate days in moderate impairment. M
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Ciprofibrate in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

